Rituximab and RASi in Patients with IgAN

PHASE4CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

March 30, 2024

Study Completion Date

March 30, 2024

Conditions
IgA Nephropathy
Interventions
DRUG

Rituximab

To evaluate the efficacy and safety of HLX01 combined with RASi in patients with IgAN.

DRUG

RAS 2410

To evaluate the efficacy and safety of RASi in patients with IgAN.

Trial Locations (1)

Unknown

Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Dongfang Hospital Affiliated to Tongji University

OTHER

collaborator

Shanghai Pudong New Area People's Hospital

OTHER

collaborator

Ruijin Hospital North Shanghai Jiao Tong University School of Medicine

UNKNOWN

collaborator

Ningbo Municipal Yinzhou District No.2 Hospital

OTHER

collaborator

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Xiamen Hong'ai Hospital

UNKNOWN

collaborator

Sir Run Run Shaw Hospital

OTHER

collaborator

Tongji Hospital

OTHER

collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

lead

Nan Chen,MD

OTHER

NCT04525729 - Rituximab and RASi in Patients with IgAN | Biotech Hunter | Biotech Hunter